BCA
KIN

Berman Capital Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History

Berman Capital Advisors’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-177
Closed – – 1908
2020
Q1 		$0 Hold
177
– – ﹤0.01% 1758
2019
Q4 		$1K Hold
177
– – ﹤0.01% 1433
2019
Q3 		$1K Buy
+177
New +$1.3K ﹤0.01% 1408

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Berman Capital Advisors's KIN Position: Q2 2020 in Review

Berman Capital Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q2 2020, closing a stake of 177 shares.

Berman Capital Advisors first reported a position in KIN in Q3 2019 and held it in 3 quarters. The position peaked at $1K in Q4 2019. 83 funds tracked by Wall St. Rank hold KIN as of Q2 2020.

  • Berman Capital Advisors reported no remaining Kindred Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
  • Berman Capital Advisors sold 177 Kindred Biosciences, Inc. shares in Q2 2020.
  • Berman Capital Advisors first reported a position in Kindred Biosciences, Inc. in Q3 2019 and held it in 3 quarters.
  • Berman Capital Advisors's Kindred Biosciences, Inc. position peaked at $1K in Q4 2019.
  • 83 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2020.

Based on Berman Capital Advisors's 13F filing for Q2 2020, filed 6 Aug 2020.